Last reviewed · How we verify
NCT06332170
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
Phase 1 trial testing HS-20093 in Advanced Solid Tumor in 610 participants. Currently enrolling.
30 May 2026
Quick facts
| Lead sponsor | Hansoh BioMedical R&D Company |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 610 |
| Start date | 26 April 2024 |
| Primary completion | 30 May 2026 |
| Estimated completion | 30 May 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- HS-20093 — full drug profile →
- Adebrelimab — full drug profile →
- Cisplatin/ Carboplatin
- Cetuximab (cetuximab) — full drug profile →
- Enzalutamide (enzalutamide) — full drug profile →
Conditions studied
- Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Sponsor
Hansoh BioMedical R&D Company — full company profile →
Who can join
18 and older, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced solid tumor patients.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Non-immune functions of B7-H3: bridging tumor cells and the tumor vasculature.
Wu S, Hu C, Hui K, Jiang X. · · 2024 · cited 12× · PMID 38952550 · DOI 10.3389/fonc.2024.1408051 -
B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer.
Ju Y, Watson J, Wang JJ, Yen YT, et al · · 2025 · cited 10× · PMID 39914189 · DOI 10.1016/j.drup.2025.101207 -
Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment.
Marchesi S, Marinello A, Ambrosini P, Cavalli C, et al · · 2025 · PMID 40603576 · DOI 10.1038/s41698-025-01011-7
Verify or expand the search:
- PubMed search for NCT06332170
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HS-20093
Trials testing the same drug.
- NCT07464327 — A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With A · Phase 3 · not yet recruiting
- NCT07186452 — Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT06963502 — A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT06935409 — Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-li · Phase 3 · active not recruiting
- NCT06699576 — ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. · Phase 1 · not yet recruiting
Other recruiting trials for Advanced Solid Tumor
Currently open trials in the same condition.
- NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
- NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
- NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting
Other Hansoh BioMedical R&D Company trials
Trials by the same sponsor.
- NCT07464327 — A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With A · Phase 3 · not yet recruiting
- NCT07462923 — HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma · Phase 1 · recruiting
- NCT07283367 — A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. · Phase 1, PHASE2 · not yet recruiting
- NCT07186452 — Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT06844799 — A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06332170 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hansoh BioMedical R&D Company
- Last refreshed: 18 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06332170.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing